Medibank was formally notified Tuesday of a class action-style complaint brought on behalf of millions of customers in the wake of last month’s massive data breach.
A contradictor has argued that the High Court must consider the reputation of Botox maker Allergan’s trade marks in a cosmetic company’s challenge to a judgment finding it infringed the marks by marketing its topical creams as Botox alternatives.
Expanding their campaign to recoup alleged unpaid overtime pay for junior doctors, law firms Gordon Legal and Hayden Stephens & Associates have launched two new class actions against hospital operators.
A contradictor in two pelvic mesh class actions against Johnson & Johnson has opposed Shine Lawyers recovering $100 million in costs from a $300 million settlement, which a judge has preliminarily found is not fair and reasonable to group members.
Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.
Medibank faces a representative proceeding over last month’s data breach that exposed the sensitive information of millions of customers, as the private health insurer reveals more stolen data was posted online overnight.
The maker of Vagisil personal care products has filed a trade mark suit against pharmaceuticals and cosmetic company Dr Wolff over its new line of Vagisan products, arguing the name is likely to confuse consumers.
Australian pharmaceutical company AUPharma has sued the international arm of Purdue, alleging it was wrongly granted patent extensions for several oxycodone products marketed as Targin.
A judge has dismissed a class action brought against animal health giant Zoetis over alleged side effects resulting from its Hendra virus horse vaccine, finding there were “too many uncertainties” in the applicant’s evidence.
The operator of the Royal Perth Hospital has brought legal action against Griffith Hack alleging the law firm contributed to the “dishonest and fraudulent design” of a leading researcher to transfer the intellectual property rights to a stem cell manufacturing method developed inhouse.